Thyrotoxic periodic paralysis in an adolescent male: A case report and literature review.

Luke He

Veronica Lawrence  
*Children's Mercy Hospital*

Wayne V. Moore  
*Children's Mercy Hospital*

Yun Yan  
*Children's Mercy Hospital*

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the [Emergency Medicine Commons](https://scholarlyexchange.childrensmercy.org/collections/emergency-medicine), [Endocrinology, Diabetes, and Metabolism Commons](https://scholarlyexchange.childrensmercy.org/collections/endocrinology-diabetes-metabolism), and the [Pediatrics Commons](https://scholarlyexchange.childrensmercy.org/collections/pediatrics)

**Recommended Citation**

He L, Lawrence V, Moore WV, Yan Y. Thyrotoxic periodic paralysis in an adolescent male: A case report and literature review. Clin Case Rep. 2020;9(1):465-469. Published 2020 Nov 23. doi:10.1002/ccr3.3558

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Thyrotoxic periodic paralysis in an adolescent male: A case report and literature review

Luke He1,2 | Veronica Lawrence2,3 | Wayne V. Moore2,4 | Yun Yan2,4

1Department of Emergency Medicine, Creighton University, Phoenix, AZ, USA
2School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA
3Department of Emergency, Children’s Mercy, Kansas City, MO, USA
4Department of Endocrinology, Children’s Mercy, Kansas City, MO, USA

Correspondence
Yun Yan, Division of Endocrinology, Department of Pediatrics, Children’s Mercy, School of Medicine, UMKC, 3101 Broadway Blvd, Kansas City, MO 64111, USA.
Email: yyan@cmh.edu

1 | INTRODUCTION

Thyrotoxic periodic paralysis (TPP) is an uncommon hyperthyroidism-related condition characterized by abrupt onset muscle weakness and hypokalemia resulting from rapid intracellular shift of potassium. TPP is primarily reported in adult males in Asian populations, including Chinese, Japanese, Vietnamese, Filipino, and Korean.1,2 Its incidence in non-Asian populations such as Caucasians, African Americans, and Hispanics is very low. PTT is very rarely seen in the pediatric population.3 A number of TPP cases in adults have been reported in Western countries recently. TPP is commonly misdiagnosed in Western countries because of its similarities to familial periodic paralysis.4 We report a case of an Asian adolescent male presenting with acute-onset paralysis and severe hypokalemia and highlight the importance of recognizing TPP.

2 | CASE REPORT

A 17-year-old Vietnamese American male presented to the emergency department after an episode of syncope, muscle weakness, and difficulty breathing. Two months prior, he began having episodes of tachycardia and was subsequently evaluated by Cardiology. He was diagnosed with Graves’ disease with a TSH of 0.007 mIU/mL, free T4 > 7 ng/dL (0.8-1.9), and positive thyroid-stimulating immunoglobulin and was started on atenolol. He was then seen by Endocrinology and started on methimazole 10 mg, 3 times daily. Thyroid ultrasonography revealed markedly increased internal vascularity within the thyroid gland. On the next morning, he reported feeling weak. His father found him on the floor of his bedroom, weak and unable to move, approximately 30 minutes after his father “heard a thud upstairs.” He recalled that his legs “gave out” and he “hit his face on a table”. In the emergency department on presentation, he was tachycardic at...
| #  | Age | Ethnic | Sex | K⁺ (mmol) | T3 (ng/dL) | FT4 (ng/dL) | TT4 (µg/dL) | TSH (mU/L) | Therapy                                      | Recurrent paralysis after discharge | Reference       |
|----|-----|--------|-----|-----------|------------|-------------|-------------|-------------|---------------------------------------------|-------------------------------------|----------------|
| 1  | 16  | Chinese| M   | 2.0       | 404        | NA          | 16.5        | <0.03       | Propranolol, methimazole, RIA               | 0.5 yr follow-up: none              | Miller et al10 |
| 2  | 14  | Chinese| M   | 2.2       | 840        | 1.98        | NA          | <0.03       | Propranolol, carbimazole                    | NA                                  | Wong et al11   |
| 3  | 15  | Vietnamese| M  | 1.8       | NA         | 4.66        | NA          | 0.001       | Carbimazole, thyroxine                      | NA                                  | Schalin-Jantti et al15 |
| 4  | 14  | Korean | F   | 2.3       | 183        | 3.8         | NA          | 0.01        | β-adrenergic blocker, antithyroid drug      | 3 yr follow-up: none                | Oh et al8      |
| 5  | 16  | Korean | M   | 2.5       | 180        | 1.87        | NA          | 0.09        | Methimazole                                  | 2 recurrent episodes               | Ahn et al13    |
| 6  | 17  | Korean | M   | 2.2       | 285        | 3.43        | NA          | <0.01       | Propranolol, methimazole                    | 1 recurrent episode                | Cho et al14    |
| 7  | 13  | Asia   | M   | 2         | 253        | 5.72        | NA          | NA          | Propranolol, methimazole                    | NA                                  | Jones et al15  |
| 8  | 16  | Korean | M   | 2.7       | 295        | 2.1         | NA          | <0.025      | Propranolol, methimazole                    | 1 yr follow-up: none                | Jung et al6    |
| 9  | 17  | Hispanic| M  | <3.5      | >800       | NA          | 22.4        | <0.01       | β-adrenergic blocker, methimazole           | 1 yr follow-up: none                | Al-Zubeidi et al12 |
| 10 | 15  | Hispanic| M  | 1.5       | 608        | NA          | 23.8        | 0.04        | Methimazole                                  | 3 yr follow-up: none                | Al-Zubeidi et al12 |
| 11 | 15  | Chinese| M   | 1.6       | 240        | 2.8         | 12.6        | 0.008       | Methimazole, atenolol                       | NA                                  | Thornton et al25 |
| 12 | 16  | Korean | M   | 2.5       | 246        | 2.46        | NA          | <0.008      | Methimazole                                  | 2 yr follow-up: none                | Roh et al9     |
| 13 | 14  | Korean | M   | 3.1       | 615        | 4.97        | NA          | 0.06        | Propranolol, propylthiouracil               | 3 yr follow-up: none                | Roh et al9     |
| 14 | 14  | African American| M | 2        | >651       | >7          | 16.8        | <0.005      | Propranolol, methimazole                    | 0.5 yr follow-up: none              | Glass et al7   |
| 15 | 17  | Vietnamese| M  | 1.6       | NA         | >7          | NA          | 0.007       | Methimazole, atenolol, RIA                  | 2 yr follow-up: none                | In this report |

Abbreviations: FT4, Free T4; NA, not available; RIA, radioiodine ablation; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; TT4, total T4.
116 bpm, blood pressure 131/50 mm Hg with respiratory rate 24 BR/min. He had diffused and significant muscle weakness in all extremities, including grip strength. He was alert and awake without complaint of headache, and physical exam revealed no papilledema during the emergency department and PICU stay; therefore, no brain imaging was obtained.

Basic metabolic panel revealed potassium 1.6 mmol/L (3.5–5.2) and magnesium 1.6 mmol/L (1.6–2.3). The rest of his metabolic panel was unremarkable. He had EKG changes consistent with hypokalemia with U waves. The EKG also revealed an atrial rhythm with first degree AV block, intraventricular conduction delay, and QTc prolongation at 588 (<450). His chest X-ray was normal. Normal saline was administered, and potassium replacement was given with 40 mEq of KCl followed by D5 NS with 40 mEq/L KCl at the maintenance rate (90 mL/hr). He was also given one dose of magnesium intravenously. His potassium level returned to normal range at 4.6 mmol/L and muscle strength returned completely after 24 hours of treatment. Four months after he was discharged home, he underwent radioactive iodine ablation, which he tolerated well. He is now 2 years status post radioactive iodine ablation and has not had a recurrent paralysis episode. He takes thyroid hormone replacement daily and is doing well.

3 ▪ DISCUSSION

Because TPP is not often seen in the United States and other Western countries, it can be easily missed. Hypokalemia, in particular, has broad differential diagnoses. Our patient was an Asian American recently diagnosed with Graves’ disease, who presented with tachycardia and significant weakness in all extremities. His laboratory evaluation revealed hypokalemia. His EKG revealed changes consistent with hypokalemia including U waves.

The age of onset of TPP symptoms is typically between 20 and 39 years. TPP is very rare in children and adolescents, making the diagnosis in this age group challenging. In the past 2 decades, fewer than 20 cases of TPP in adolescents have been reported. Ethnicities represented include Chinese, Hispanic, Korean, and Vietnamese. One case was recently reported in a 14-year-old African American boy. Among previously reported cases of pediatric TPP (Table 1), only one patient was female. All 15 patients had Graves’ disease and hypokalemia, and potassium was usually less than 3.0 mmol/L (potassium was 1.6 mmol/L in our case). The degree of initial hypokalemia has a direct correlation with the severity of paralysis. Our patient presented with shortness of breath and tachycardia. Fatal ventricular arrhythmia and respiratory failure have been reported. To avoid such fatal complications, early recognition and prompt treatment is essential. In the review of previously reported cases, the 15 adolescents recovered well from TPP and only two cases had a recurrent episode after discharge (Table 1).

The pathogenesis of TPP is not entirely clear. Recent studies have shown that TPP is a channelpathy related to mutations in the KCNJ18 gene encoding Kir2.6, a skeletal muscle-specific Kir channel protein. Mutant Kir2.6 proteins significantly reduce cell membrane abundance and could interfere with the excitability of skeletal muscle cells. TTP is more commonly reported in Asian males, with onset usually in the third decade of life. More than 95% of TPP is found in men, despite most thyrotoxicosis being found in women. TPP patients may present with hypokalemia, as did our patient, due to the intracellular shift of potassium throughout the body when the Na+/K+–ATPase activity in the cell membrane goes awry and is hyperactivated, as it does when influenced by beta-adrenergic catecholamines or insulin, which may explain why hypokalemia presents in patients in a hyperadrenergic state secondary to hyperthyroidism. TPP episodes usually occur during rest after exercise or after a high-carbohydrate meal.

Hypophosphatemia and hypomagnesemia may also be present in patients with TPP, contributing to weakness. Our patient had normal phosphorus and low normal magnesium. In TPP the total body potassium is unchanged, unlike other conditions such as decreased potassium intake or losses of potassium through sweat, urine, or gastrointestinal tract. The differential should also include neurological etiologies anywhere, including the brain, the spinal cord, the peripheral nerves, and the neuromuscular junction. The cause of both the weakness and cardiac conduction abnormalities seen in TPP is hypokalemia. Patients with TPP may experience a spectrum of symptoms including muscle aches, soreness, weakness, and flaccid paralysis. The attacks generally begin at the lower extremities and then move to girdle muscles and upper limbs, without sensory deficits. Deep tendon reflexes are diminished or absent, as seen in our patient’s initial presentation. Acute neuromuscular paralysis related to hypokalemia is an important clinical entity with diverse etiology, but the treatment and prognosis differ depending on the etiology. A differential may include familial hypokalemic periodic paralysis (FHPP), which typically occurs earlier in life and is more likely to have a family history. Electrocardiogram changes may include sinus tachycardia due to the hyperadrenergic state, prolonged QT-U interval due to hypokalemia, and prolonged PR due to thyrotoxicosis.

Because TPP is not often seen in Western countries, the diagnosis can easily be missed. Our patient was an Asian American and recently diagnosed with Graves’ disease. He presented with tachycardia and notable muscle weakness in all extremities. His laboratory evaluation revealed hypokalemia and hypomagnesemia, and his EKG revealed changes consistent with hypokalemia and U waves.
Stabilization of patients with TPP should emphasize cardiac abnormalities and normalization of serum potassium. Potassium replacement is necessary immediately. After initial administration of potassium, most patients will have an increase in potassium, while up to 25% of patients may have an initial drop with stabilization over a few hours. Rebound hyperkalemia can occur during potassium supplementation. Excessive doses of potassium can lead to hyperkalemia once potassium shifts to the extracellular space. If potassium supplement is not enough, some reports suggest using IV or oral propranolol for reversing the hypokalemia via blocking the beta-adrenergic receptor. This treatment may also prevent attacks before an euthyroid state is reached.25

4 | CONCLUSION
Thyrotoxic periodic paralysis is a rare cause of acute paralysis and can lead to cardiac arrhythmias and death without accurate diagnosis and appropriate treatment. Since TPP is rare in Western countries, especially among pediatric patients, many physicians may be unfamiliar with this condition. Efficient evaluation and timely treatment is crucial to prevent complications, especially fatal arrhythmias. Acute paralysis with hypokalemia should also prompt physicians to evaluate thyroid function as a differential diagnosis.

ACKNOWLEDGMENT
We thank the Medical Writing Center at Children’s Mercy Kansas City for editing this manuscript.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
YY and VL: managed the patient. LH: led data collection, conducted literature search, and wrote the initial draft of the manuscript. LH, VL, WVM and YY: edited the draft into this manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

ETHICAL APPROVAL
Written consent was obtained from the patient’s parents.

DATA AVAILABILITY STATEMENT
All data generated or analyzed during this study are included in this published article or in the data repositories listed in references.

ORCID
Yun Yan https://orcid.org/0000-0003-2605-8860

REFERENCES
1. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. J Thyroid Res. 2014;2014:649502.
2. McFadzean AJ, Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. BMJ. 1967;1(5538):451-455.
3. Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine. 1992;71(3):109-120.
4. Lam L, Nair RJ, Tingle L. Thyrotoxic periodic paralysis. Proc (Bayl Univ Med Cent). 2006;19(2):126-129.
5. Jones P 3rd, Papadimitropoulos L, Tessaro MO. Thyrotoxic periodic paralysis in a pediatric patient. Pediatr Emerg Care. 2014;30(1):35-37.
6. Jung SY, Song KC, Shin JI, Chae HW, Kim HS, Kwon AR. A case of thyrotoxic periodic paralysis as initial manifestation of Graves’ disease in a 16-year-old Korean adolescent. Ann Pediatr Endocrinol Metab. 2014;19(3):169-173.
7. Glass J, Osipoff J. Thyrotoxic periodic paralysis presenting in an African-American teenage male: case report. Int J Pediatr Endocrinol. 2020;2020:7.
8. Oh KW, Jeong JY, Kim JS. A case of thyrotoxic periodic paralysis in adolescent with Graves’ disease. L Korean Soc Pediatr Endocrinol. 2011;16:5.
9. Roh JG, Park KJ, Lee HS, Hwang JS. Thyrotoxic hypokalemic periodic paralysis due to Graves’ disease in 2 adolescents. Ann Pediatr Endocrinol Metab. 2019;24(2):133-136.
10. Miller JD, Quillian W, Cleveland WW. Nonfamilial hypokalemic periodic paralysis and thyrotoxicosis in a 16-year-old male. Pediatrics. 1997;100(3 Pt 1):412.
11. Wong GW, Leung TF, Lo AF, Ahuja AT, Cheng PS. Thyrotoxic periodic paralysis in a 14-year-old boy. Eur J Pediatr. 2000;159(12):934.
12. Al-Zubeidi H, Demeterco C, Jones KL. Thyrotoxic hypokalemic periodic paralysis (THPP) in adolescents. J Pediatr Endocrinol Metab. 2015;28(1-2):157-161.
13. Ahn MBY, Lee MH, Cho WK, Suh BK. A case of thyrotoxic periodic paralysis in a 16-year-old adolescent. Ann Pediatr Endocrinol Metab. 2012;17(2):5.
14. Cho TH, Kim SC, Kim SJ. A case of thyrotoxic periodic paralysis in 17-year-old adolescent. J Korean Child Neurol Soc. 2013;21(2):68-72.
15. Schalin-Jantti C, Laine T, Valli-Jaakola K, Lonqvist T, Kontula K, Valimaki MJ. Manifestation, management and molecular analysis of candidate genes in two rare cases of thyrotoxic hypokalemic periodic paralysis. Horm Res. 2005;63(3):139-144.
16. Lee JI, Sohn TS, Son HS, et al. Thyrotoxic periodic paralysis presenting as polymorphic ventricular tachycardia induced by painless thyroiditis. Thyroid. 2009;19(12):1433-1434.
17. Qian YY, Dai ZJ, Zhu C, Zhu YX, Wu CM. Thyrotoxic periodic paralysis complicated by life-threatening acute hypercapnic respiratory failure in a Chinese male with painless thyroiditis. Am J Emerg Med. 2019;37(2):379 e371-379 e373.
18. Paninka RM, Carlos-Lima E, Lindsey SC, Kunii IS, Dias-da-Silva MR, Arcisio-Miranda M. Down-regulation of Kir2.6
channel by c-termini mutation D252N and its association with the susceptibility to Thyrotoxic Periodic Paralysis. *Neuroscience*. 2017;346:197-202.

19. Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. *Cell*. 2010;140(1):88-98.

20. Kelley DE, Gharib H, Kennedy FP, Duda RJ Jr, McManis PG. Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. *Arch Intern Med*. 1989;149(11):2597-2600.

21. Kodali VR, Jeffcote B, Clague RB. Thyrotoxic periodic paralysis: a case report and review of the literature. *J Emerg Med*. 1999;17(1):43-45.

22. Ko GT, Chow CC, Yeung VT, Chan HH, Li JK, Cockram CS. Thyrotoxic periodic paralysis in a Chinese population. *QJM*. 1996;89(6):463-468.

23. Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. *Am J Med*. 1990;88(6):642-646.

24. Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. *J Clin Endocrinol Metab*. 2006;91(7):2490-2495.

25. Thornton MD. Lower-Extremity Weakness in a Teenager Due to Thyrotoxic Periodic Paralysis. *The Journal of emergency medicine*. 2017;52(4):e133-e137.

**How to cite this article:** He L, Lawrence V, Moore WV, Yan Y. Thyrotoxic periodic paralysis in an adolescent male: A case report and literature review. *Clin Case Rep*. 2021;9:465–469. [https://doi.org/10.1002/ccr3.3558](https://doi.org/10.1002/ccr3.3558)